Hematocrit Management on TRT: The Polycythemia Question

Hematocrit is the number that ends more testosterone therapy than it should. A man gets a routine panel back, sees a red flag next to a figure in the high forties, and is told to stop. In most cases stopping was not the indicated action, the number was not dangerous, and the underlying reason it rose was never looked for. Hematocrit elevation on TRT is real, it is worth monitoring, and it is one of the most manageable findings in hormone medicine — provided you know what the thresholds actually are and what is driving the rise.

The mechanism, and why it is not a complication

Testosterone increases erythropoietin production by the kidney, which signals bone marrow to make more red cells. It also suppresses hepcidin, the hormone that restricts iron availability, which means more iron reaches the marrow to be used. Both effects push in the same direction, and hematocrit — the percentage of blood volume made up of red cells — rises accordingly (Bachman et al., J Gerontol A Biol Sci Med Sci 2014).

This is normal androgen physiology, not a toxic effect. It is the same reason men have higher hematocrit than women at every age. What makes it clinically interesting is not that it happens but how far it goes, and that turns out to depend less on the drug than on how the drug is delivered.

Peak concentration, rather than average concentration, does most of the driving. High-dose intramuscular injections every two weeks produce a large supraphysiologic peak in the days afterwards, and that peak is what stimulates erythropoietin. Weekly or twice-weekly subcutaneous protocols deliver the same weekly amount with a much flatter curve and reliably produce smaller rises that then stabilise (Ohlander et al., Sex Med Rev 2018). This is the single most useful fact in the whole topic, because it means the first lever is usually schedule, not dose. Subcutaneous versus intramuscular delivery covers the pharmacokinetics in full.

The actual thresholds

Most men see hematocrit rise from a baseline around 44% into the mid-to-upper 40s and then plateau there. That is the expected course, not a warning sign.

Two thresholds circulate in practice: >52% from FDA labelling and >54% in much of clinical use. The gap between them is where most of the unnecessary discontinuation happens. A value of 51% is not the same clinical object as a value of 57%, and treating them identically is how a manageable finding becomes a stopped therapy.

One technical point that matters more than it should: hematocrit is a ratio, so it moves with plasma volume. A dehydrated draw, a morning sample after a long fast, or a hot day can inflate it by a couple of points without a single extra red cell existing. A single elevated value near a threshold should be repeated, well hydrated, before anything is done about it.

What the risk actually is

The fear is that thick blood causes clots. The physiological basis is real — blood viscosity rises non-linearly with hematocrit, so each additional point matters more than the one before it. But the point at which that becomes clinically meaningful is higher than the discussion usually implies. Clinically important thrombotic risk emerges above roughly 55%, and typically in the presence of other risk factors. Analyses of large TRT cohorts have found minimal cardiovascular event increase even in the 50-54% range in otherwise healthy men, and the TRAVERSE trial, which monitored hematocrit closely, did not show an excess of clotting events on treatment (Lincoff et al., N Engl J Med 2023).

Individual context still changes the calculus. A man with prior deep vein thrombosis or pulmonary embolism, atrial fibrillation, active smoking, or polycythemia vera has legitimate reason to run lower, and the thresholds above should be pulled down accordingly. The general point is that the population risk at modest elevation is small; the personal risk depends on what else is true about you. The wider side-effect picture puts this in proportion against the other things worth monitoring.

Find the driver before treating the number

Hematocrit rarely climbs for one reason. Sorting the contributors is what turns management from repeated blood draws into a fix.

• Sleep apnea. The most important item on this list. Undiagnosed obstructive sleep apnea causes intermittent nocturnal hypoxia, which is a far more potent erythropoietin stimulus than testosterone is (obstructive sleep apnoea and secondary erythrocytosis, PubMed). Snoring, witnessed apneas, morning headaches or unrefreshing sleep in a man with a hematocrit above 54% should trigger testing rather than another phlebotomy.
• Dehydration. Inflates the ratio without changing red cell mass.
• Dose. The effect is dose-dependent; more testosterone raises hematocrit faster and higher.
• Route and frequency. Intramuscular produces higher peaks than subcutaneous; fortnightly dosing produces higher peaks than weekly or twice-weekly.
• Smoking and COPD. Both raise hematocrit independently, through the same hypoxic pathway as apnea.
• Altitude. Living high raises baseline, permanently and appropriately.

The management sequence

Worked in order, cheapest and most reversible first.

1. Monitor at month 3, 6, 12, then annually (Bhasin et al., J Clin Endocrinol Metab 2018). Most of the rise happens in the first six months and then plateaus.
2. Repeat a borderline value properly hydrated before acting on it.
3. Hydrate — above roughly 2.5 L of water daily.
4. Test for sleep apnea if any risk factors are present.
5. Switch intramuscular to subcutaneous to flatten the peak.
6. Increase injection frequency — twice weekly produces lower peaks than once weekly at the same weekly amount.
7. Donate blood every 8-12 weeks where eligible. The most efficient single intervention, and it does something useful with the blood.
8. Therapeutic phlebotomy at a similar interval where donation is not possible.
9. Reduce the dose if the above is not sufficient.
10. Discontinue only as a last resort, and only after the preceding nine steps have genuinely been tried.

Repeated phlebotomy has a cost worth naming: each removal takes iron with it, and men on a frequent schedule can drift into iron deficiency with fatigue that looks exactly like the low testosterone they were being treated for. If phlebotomy is running every 8-12 weeks indefinitely, ferritin belongs on the panel, and the underlying driver deserves another look.

What to expect over the first year

The rise is front-loaded. Most of the change appears between months two and six, then flattens as the system finds a new equilibrium — a hematocrit still climbing steadily at month twelve is a signal to look harder for a second driver. A change of route or frequency takes roughly two to three months to show its full effect, because that is about the lifespan of the red cells already in circulation. Phlebotomy drops the number immediately and it climbs back over a similar span, which is exactly why phlebotomy alone is management rather than a solution. The first thirty days sets out what else moves on this timeline.

Bottom line

Testosterone raises red cell production through erythropoietin and hepcidin, and a modest rise into the upper forties is the expected response rather than a complication. The thresholds that matter are >52% for attention and >54% for action, and the risk at modest elevation is considerably smaller than the concern attached to it. Before treating the number, find the driver — sleep apnea above all, then hydration, then peak concentration from route and injection frequency. Flatten the peaks, fix the apnea, donate blood if needed, and check iron if phlebotomy becomes routine. Stopping therapy is a last resort, not a first response, and it is chosen far more often than the evidence supports.

Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.